Drug Discovery Featured Articles & Applications

1. Why VCs Are Investing In Cheaper "Generic" LLMs For Drug Discovery 11/17/2025

   VCs are looking to invest in cheaper, generic LLMs rather than expensive, customized LLMs in drug discovery.

2. Live Insights: 45% Believe The NAMs Industry Should Expand Pre-Competitive Data Sharing Programs 11/13/2025

   According to a recent poll, 45% of participants believe the NAMs industry should expand pre-competitive consortia by sharing validation data and best practices to reduce duplication and accelerate acceptance. Experts Zahar Nahle, Ph.D. and Samantha Atkins, Ph.D. share their insights.

3. Progressing Precision Medicine Discovery With AI 11/12/2025

   We caught up with Iya Khalil, Ph.D., vice president and head of data, AI, and genome sciences at Merck & Co. to discuss Merck's creation of a foundation model that will help progress precision medicine.

4. Tapping Into Nature's Pharmacy To Develop Safer Antiseizure Medications? 11/11/2025

   We caught up with Colleen Carpenter-Swanson, Ph.D., University of Richmond, to discuss the use of zebrafish models to investigate whether vitexin can be used in antiseizure medications.

5. How Can We Develop New Treatments For Patients With Early Breast Cancer? 11/10/2025

   Intensity Therapeutics has developed a new approach to treating cancer — a therapy injected directly into tumors that kills cancer and stimulates a potent anticancer immune response.

6. When One Gene Isn't Enough: The Case For Gene-Agnostic Vision Rescue 11/7/2025

   The genetic diversity of retinitis pigmentosa challenges the one-gene-one-therapy model and positions RP as a proving ground for gene-agnostic treatments designed to preserve or restore visual function across genotypes.

7. Notes From A VC: What It Takes To Be Impactful In Longevity Science 11/6/2025

   Impact in longevity science (particularly for cell and gene therapies) is not about chasing the next unicorn; it is about carrying transformative ideas across the threshold of scientific validation, regulatory trust, and societal acceptance.

8. Protein Degraders Redefine ADME And Drug Disposition Dynamics 11/5/2025

   ADME principles have been recently challenged by the emergence of protein degraders, or proteolysis-targeting chimeras (PROTACs), which can benefit from an ABDE framework instead.

9. OpenFold3 Released: Redefining The Limits Of Protein Prediction Models 11/4/2025

   OpenFold3, a biomolecular structure prediction model based on AlphaFold3 was recently released by the OpenFold Consortium, a non-profit AI R&D organization.

10. Returning To Nature: Discovering The Next Generation Of Medicines 11/4/2025

    Researchers at Kapoose Creek Bio are looking to use nature, specifically fungi, to treat mental health and neurodegenerative disorders.